Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial

The addition of veliparib to a highly active platinum doublet, with continuation as monotherapy if the doublet were discontinued, resulted in significant and durable improvement in progression-free survival in patients with germline BRCA mutation-associated advanced breast cancer. These data indicate the utility of combining platinum and PARP inhibitors in this patient population.

Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial

PURPOSE To report the long-term results of external-beam accelerated partial-breast irradiation (APBI) intensity-modulated radiation therapy (IMRT) Florence phase III trial comparing whole-breast irradiation (WBI) to APBI in early-stage breast cancer. PATIENTS AND METHODS The primary end point was to determine the 5-year difference in ipsilateral breast tumor recurrence (IBTR) between 30 Gy in 5…

HER2 Blockade Regimen Appears Superior as Treatment of HER2+ HR+ Metastatic Breast Cancer

Frontline trastuzumab plus lapatinib and an aromatase inhibitor demonstrated superior progression-free survival compared with the trastuzumab/aromatase inhibitor alone as treatment of patients with HER2-positive, HR-positive metastatic breast cancer.

Novel Therapies in the Management of HER2-Positive Breast Cancer

Interview with Reshma L. Mahtani DO

Patient Treatment and Outcome After Breast Cancer Orbital and Periorbital Metastases

Written by Lillie D Shockney RN, BS, MAS, ONN-CG

New Therapy Targets Breast Cancer Metastases in Brain

A Novel Testing & Prevention Model

A Novel Testing & Prevention Model

TAILORx study finds early, abrupt cognitive decline among patients with breast cancer

Click on the article title to read more.

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

The management of human epidermal growth factor receptor (HER2)–positive breast cancer (BC) has rapidly evolved over the last 20 years. Major advances have led to US Food and Drug Administration appr…

GWAS Identifies Risk Loci for Breast Cancer Subtypes

Montserrat Garcia-Closas and colleagues report findings from a new genome-wide association study (GWAS) for breast cancer identifying 32 novel susceptibility loci. Importantly, this study reveals genetic risk for breast cancer subtypes and expands the potential for the development of subtype-specific polygenic risk scores.